Wednesday, May 24, 2000

8:00-9:30AM		CONTRIBUTED PODIUM PRESENTATIONS
		METHODOLOGICAL ISSUES / ADVANCES
	MI1	IDENTIFYING FACTORS ASSOCIATED WITH HIGH AND LOW COST ASTHMATICS: OPPORTUNITIES FOR DISEASE MANAGEMENT USING AUTOMATIC INTERACTION DETECTION Boscarino JA, Zhao Z, Andrews KW, Sokol MC, Yao J, McGuigan KA, Gutierrez B, Refowitz, R, Merck-Medco Managed Care, Franklin Lakes, NJ, USA
	MI2	THE NUMBER NEEDED TO TREAT APPROACH: EVALUATING THE CLINICAL RELEVANCE OF FEXOFENADINE IN SEASONAL ALLERGIC RHINITIS Crawford B1, Marquis P2, Offord S3, 1MAPI Values, Boston, MA, USA; 2MAPI Values, Lyon, France; 3Aventis Pharmaceuticals, Inc, Bridgewater, NJ, USA
	MI3	RELIABILITY AND VALIDITY OF INTERNATIONAL PROSTATE SYMPTOM SCORE (I-PSS) FOR EARLY ASSESSMENT OF SYMPTOMS IN THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA (BPH) Singh A, Ashraf T, Verlinden MH, Abbott Laboratories, Abbott Park, IL, USA
	MI4	A FRAMEWORK FOR COST-EFFECTIVENESS ANALYSIS FROM CLINICAL TRIAL DATA O'Hagan A1, Stevens JW2, 1University of Sheffield, Sheffield, UK; 2AstraZeneca R&D Charnwood, Loughborough, UK
		STUDENT SESSION
	S1	IMPACT OF COMMUNITY-ACQUIRED PNEUMONIA TREATMENT GUIDELINES ON LENGTH OF STAY AND COST Merchant SV, Mullins CD, Cooke CE, Pharmacy Practice and Science, University of Maryland, School of Pharmacy, Baltimore, MD, USA
	S1	USE OF ESTROGEN REPLACEMENT THERAPY IN MARYLAND MEDICAID FEMALES Huang X, Weiss SR, Zuckerman IH, Hsu VD, School of Pharmacy, University of Maryland, Baltimore, MD, USA
	S1	STATISTICAL METHOD FOR MODELING DUAL SELECTION BIAS: WOODWORK EFFECT AND DRUG SELECTION BIAS AMONG MULTIPLE ALTERNATIVES Shi L, McCombs JS, Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
	S1	METHODS FOR COMPARING AREAS UNDER RECEIVER OPERATING CHARACTERISTIC CURVES: APPLICATION IN SCREENING ACCURACY FOR DEPRESSION Shaw JW1, Treglia M1, Motheral B2, Coons SJ2, 1Global Health Outcomes Research, Eli Lilly and Company, Indianapolis, IN, USA; 2College of Pharmacy, The University of Arizona, Tucson, AZ, USA
		BURDEN OF ILLNESS / TRIAL-BASED ECONOMIC EVALUATIONS
	BT1	POSTOPERATIVE PAIN SEVERITY AFTER ABDOMINAL OR ORTHOPEDIC SURGERY: INTERIM RESULTS Strassels S1, Chen C2, Carr D1, McDonagh M1, Gouveia W1, Wurm H1, 1New England Medical Center, Boston, MA, USA; 2Searle Pharmaceuticals, Skokie, IL, USA
	BT2	DIRECT COSTS OF OBESITY IN PORTUGAL Pereira J1, Mateus C2, Amaral, MJ2, 1National School of Public Health, New University, Lisbon, Portugal; 2Ministry of Health, Lisbon, Portugal
	BT3	THE COMPARATIVE ECONOMIC VALUE OF RALTITREXED AND 5-FU PLUS LEUCOVORIN Simons WR1, Grace EM23, 1Millennium Biostatistics, Inc., Millburn, NJ, USA; 2AstraZeneca, Mississauga, ON, Canada; 3McMaster University, Hamilton, ON, Canada
	BT4	COST-EFFECTIVENESS OF HIGH VERSUS LOW DOSE ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIs) IN THE TREATMENT OF CHRONIC HEART FAILURE (CHF): AN ECONOMIC ANALYSIS OF THE US ASSESSMENT OF TREATMENT WITH LISINOPRIL AND SURVIVAL (ATLAS) TRIAL Schwartz JS1, Wang Y2, Cleland J3, ATLAS Investigators, 1University of Pennsylvania, Philadelphia, PA, USA; 2AstraZeneca Pharmaceuticals, Wilmington, DE, USA; 3University of Kull, Cottingham, UK
		COST-EFFECTIVENESS / COST-BENEFIT ANALYSES (SESSION 2)
	CEB5	MEASURING PATIENT PREFERENCES USING CONJOINT ANALYSIS: A NEW APPROACH Phillips KA1, O'Brien B2, Skolnik H1, Johnson TR3, 1University of California-San Francisco, San Francisco, CA, USA; 2McMaster University, Hamilton, ON, Canada; 3Triangle Economic Research, Durham, NC, USA
	CEB6	THE IMPORTANCE OF COMPARABLE PATIENT POPULATIONS IN COST-EFFECTIVENESS ANALYSES: TOLTERODINE VERSUS OXYBUTININ XL FOR TREATING OVERACTIVE BLADDER Schonfeld WH1, Sheriff SK1, Levaux HP1, Williamson TE2, 1The Lewin Group, San Francisco, CA, USA; 2Pharmacia & Upjohn, Peapack, NJ, USA
	CEB7	SOCIOECONOMIC EFFICIENCY OF THE ADJUVANT TREATMENT WITH ACAMPROSATE IN MAINTAINING ABSTINENCE IN ALCOHOL DEPENDENT PATIENTS Kilburg A, Daniel D, Pfeil T, Kirchhoff D, Rychilk R, Institute of Empirical Health Economics, Burscheid, Germany
	CEB8	A DECISION ANALYTIC MODEL MEASURING THE COST-EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN HIV+ PATIENTS WITH HIGH VERSUS LOW BASELINE VIRAL LOAD: AN INDINAVIR PLUS LAMIVUDINE AND ZIDOVUDINE EXAMPLE Risebrough NA1, Oh P1, Rachlis A2, McMurchy D2, Bast M2, Doswell M2, 1HOPE Research Center, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, ON, Canada; 2HIV Health Evaluation Unit, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, ON, Canada
9:30-10:00AM		BREAK
10:00-12:30AM		THIRD PLENARY SESSION Regulation of Pharmacoeconomics and Outcomes Research in the New Millennium Moderator: Lou Garrison PhD, Vice President and Head, Health Economics & Strategic Pricing, Roche Pharmaceuticals, Palo Alto, CA, USA & Meeting Chair, Plenary Sessions "Pharmaceutical Regulation: The Early Experience of the NHS National Institute for Clinical Excellence — Where Are We Headed?" Rod Taylor BSc (Hons), MSc, PhD, Head of Appraisals, National Institute for Clinical Excellence (NICE), London, UK "US Regulation of the Pharmaceutical Industry: Can the Past Predict the Future?" Laurie Burke RPH, MPH, Chief, Regulatory Review Branch, Food and Drug Administration, CDER, DDMAC, Rockville, MD, USA "Regulation and Promotion of Outcomes Research Now and in the Future: An Industry Perspective" Paul Radensky MD, JD, Partner, Health Law Department, McDermott, Will & Emory, Miami, FL, USA
12:30PM		ADJOURNMENT